Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma
European Journal of Haematology, Volume 115, Issue 3, Page 260-265, September 2025.ABSTRACT Introduction Bendamustine‐rituximab (BR) has demonstrated efficacy and tolerability in the treatment of various indolent B‐cell lymphomas, but there is limited data regarding its outcomes in nodular lymphocyte predominant B‐cell (Hodgkin) lymphoma (NLPBL).
Alexander Robin +6 more
wiley +1 more source
Histiocyte and T‐cell‐rich B‐cell lymphoma with Langhans giant cells [PDF]
, 2002 Dimas Suárez‐Vilela +1 more
openalex +1 more source
LDL immune complexes stimulate LDL receptor expression in U937 histiocytes via extracellular signal-regulated kinase and AP-1 [PDF]
, 2003 Yuchang Fu +4 more
openalex +1 more source
An unusual acute myeloid leukemia associated with hyper IgE: another case of AML‐M5c? [PDF]
, 2001 Haematologica. 2001 Feb;86(2):216-7. An unusual acute myeloid leukemia associated with hyper IgE: another case of AML-M5c? Lima M, Orfão A, Coutinho J, Ferreira G, Freitas I, Silvestre F, Justiça B.
COUTINHO, J. +6 more
core
Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163 [PDF]
, 2005 Jeffrey A. Vos +5 more
openalex +1 more source
Clinical Images: Penetrating aortic ulceration as an initial presentation of Erdheim‐Chester disease
Arthritis &Rheumatology, Volume 77, Issue 9, Page 1274-1275, September 2025.
Jerome Razanamahery, Bernard Bonnotte
wiley +1 more source
Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy [PDF]
, 2020 Brett Schroeder +11 more
openalex +1 more source
Two Ulcers on the Chin That Developed After Fever: Quiz Case
JEADV Clinical Practice, Volume 4, Issue 4, Page 930-933, September 2025.
Viktor Capiau +3 more
wiley +1 more source
When Brown Meets White and Blue: A Quiz in Three Hues
JEADV Clinical Practice, Volume 4, Issue 4, Page 937-939, September 2025.
Chiara Battilotti +4 more
wiley +1 more source